Remibrutinib Improves Chronic Spontaneous Urticaria in Patients with Low or High Baseline IgE level

Koremasa Hayama, Allison Ramsey, Marcus Maurer, Michihiro Hide, Karine Lherriter, Artem Zharkov, Ivan Nikolaev, Syllye Haemmerle

Division of Cutaneous Science, Department of Dermatology, Niho University School of Medicine, Tokyo, Japan; 2; Center for Allergy, Niho University Ibaraki Hospital, Tokyo, Japan; 3; Rochester Regional Health, Rochester, NY, USA; 4; Department of Immunology, Charite, Universitaetsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 5; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany; 6; Department of Dermatology, Hiroshima University Hospital, Hiroshima, Japan; 7; Novartis Pharma AG, Basel, Switzerland

INTRODUCTION

• Chronic spontaneous urticaria (CSU) is characterized by the occurrence of itchy wheals (hives) and/or angioedema for at least 6 weeks and a major detrimental impact on patients’ well-being.
• Elevated Baseline IgE levels are associated with the CSU endotype with low IgE levels corresponding to autoimmunity and high IgE levels corresponding to autotolerance in the pathogenesis of CSU.
• Brutos tyrosine kinase (BTK), which is located downstream of the IgE receptor, is a cytoplasmic tyrosine kinase expressed in selected immune cells such as mast cells, basophils, B cells, macrophages, and platelets.

METHODS

• This was a dose-finding, multicentre, randomised, placebo-controlled Phase 2b study conducted at 32 sites in 17 countries with patients with CSU (Figure 1).
• Patients with CSU who were inadequately controlled (weekly Urticaria Activity Score [UAS7] ≥13) were enrolled in this study (n=155).

RESULTS

• In total 315/319 patients were randomized: 309 (99.4%) included in the full analysis and safety set, and 240 included in the primary analysis set. The median duration of baseline urticaria was 11.5 years (range, 0.1-60.5 years).

CONCLUSIONS

• Remibrutinib treatment improves CSU in patients with low or high baseline IgE levels, regardless of previous treatment response at Week 4 which was sustained up to Week 12 for all randomized doses.

CONFLICT OF INTEREST

• Employees of Novartis Pharma AG who participated in the preparation of this manuscript have received funding from AbbVie, Biogen, Celgene Corporation, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, and have received honoraria from AbbVie, Biogen, Celgene Corporation, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, and UCB. UNRELATED: The authors wish to thank all investigators and patients involved in the trial. All authors participated in the development of the poster for presentation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. Two authors, Ivan Nikolaev and Marcus Maurer, are speakers for Novartis, and Ivan Nikolaev is paid as a consultant by Novartis. The poster was presented at American Academy of Allergy, Asthma and Immunology (AAAAI), 2022 Annual Meeting, March 3-7, 2022, Louisville, Kentucky, United States, and at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Congress, September 5-8, 2022, Amsterdam, The Netherlands. This poster was obtained through Novartis Pharma AG and is an unedited version of the abstract or manuscript.